CAR NK and CAR NK-92 cells directed toward either CD19 and CD20 led to increased anti-tumor responses toward primary CLL cells, and the CD19-targeting CAR NK is currently under investigation in a clinical trial (NCT03056339) [101,102]. Here, CD19 is linked to neoplasm.